Genocea Biosciences
GNCA

From December 31, 2021 to March 31, 2022 Issuance of common stock, net Issuance of common stock under employee benefit plans

From December 31, 2020 to December 31, 2021 Issuance of common stock, net Issuance of common stock under employee benefit plans

From June 30, 2021 to September 30, 2021 Issuance of common stock, net Issuance of common stock under employee benefit plans

From March 31, 2021 to June 30, 2021 Issuance of common stock, net Issuance of common stock under employee benefit plans

From December 31, 2020 To March 31, 2021 Issuance of common stock, net Issuance of common stock under employee benefit plans

From December 31,2019 to December 31,2020 Issuance of common stock, net Issuance of common stock under employee benefit plans Conversion of preferred stock to common stock

From June 30, 2020 to September 30, 2020 Issuance of common stock, net Issuance of common stock under employee benefit plans Conversion of preferred stock to common stock

From March 31, 2020 to June 30, 2020 Issuance of common stock, net Issuance of common stock; ESPP purchase

From December 31, 2019 to March 31, 2020 Issuance of common stock, net Issuance of common stock under employee benefit plans

from December 31, 2018 to December 31, 2019 Issuance of common stock, net Issuance of common stock; ESPP purchase Exercise of stock options

from December 31, 2018 to June 30,2019 Granted Exercised Cancelled

On May 20, 2019, Genocea Biosciences, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 (the “Common Stock”) at a ratio of one-for-eight (the “Reverse Stock Split”) and to decrease the number of shares of Common Stock that the Company is authorized to issue from 250,000,000 shares to 85,000,000 shares (the “Authorized Shares Reduction”). Pursuant to the Certificate of Amendment, the Reverse Stock Split and the Authorized Shares Reduction will be effective at 12:01 a.m., Eastern Time, on May 22, 2019. The Company expects that upon the opening of trading on May 22, 2019, the Company’s Common Stock will begin trading on a post-split basis under the CUSIP number 372427401.

from December 31, 2018 to March 31, 2019 Issuance of common stock, net of issuance costs Exercise of stock options

from December 31, 2017 to December 31, 2018 Issuance of common stock, net of issuance costs of $1 Issuance of common stock; ESPP purchase

from December 31, 2016 to December 31, 2017 Issuance of common stock, net of issuance costs of $1 Issuance of common stock; ESPP purchase Exercise of stock options Vesting of restricted stock

from December 31, 2015 to December 31, 2016 Issuance of common stock, net of issuance costs of $3 Issuance of common Stock; ESPP purchase Exercise of stock options Vesting of restricted stock

from December 31, 2014 to December 31, 2015 Issuance of common stock upon secondary public offering, net of issuance costs of $509 Issuance of common Stock; ESPP purchase Exercise of stock options Vesting of restricted stock

On August 4 2015, the Company completed an underwritten public offering of its Common Stock in which it sold an aggregate of 3,850,000 shares of Common Stock to the public at a price of $13.00 per share.

from December 31, 2013 to December 31, 2014 Conversion of redeemable convertible preferred stock into common stock Effective upon the closing of our IPO on February 10, 2014, each share of our Series C preferred stock converted into our common stock on a 1-to-0.08 basis in connection with the 1-for-11.9 reverse stock split of our common stock effected on January 21, 2014.

Effective upon the closing of our IPO on February 10, 2014, each share of our Series C preferred stock converted into our common stock on a 1-to-0.08 basis in connection with the 1-for-11.9 reverse stock split of our common stock effected on January 21, 2014.

a 1-for-11.9 reverse split of our common stock and a proportionate adjustment to the rates at which our preferred stock converts into common stock effected on January 21, 2014;the conversion of all of our shares of our preferred stock outstanding at November 30, 2013 into 11,389,725 shares of common stock, which will occur automatically upon the closing of this offering;

On January 21, 2014, the Board of Directors and stockholders approved a 1-for-11.9 reverse stock split of the Company's Common Stock, which was effected on January 21, 2014.

from December 31,2012 to December 31,2013 Issuance of Series C Preferred stock Exercise of stock options Vesting of restricted stock

from December 31, 2012 to September 30, 2013 Issuance of Series C Preferred stock Exercise of stock options